16:43 , Sep 21, 2018 |  BC Week In Review  |  Clinical News

Eureka's ET140202 leads to tumor regression in Phase I for HCC

Eureka Therapeutics Inc. (Emeryville, Calif.) said ET140202 led to one case of complete tumor regression and two cases of partial tumor regression in six evaluable patients with alpha fetoprotein (AFP)-positive hepatocellular carcinoma (HCC) in a...
23:11 , Jun 7, 2018 |  BC Week In Review  |  Clinical News

Exact HCC assay significantly better than SOC

Exact Sciences Corp. (NASDAQ:EXAS) reported data showing that its hepatocellular carcinoma blood test had greater sensitivity and specificity in identifying HCC, especially early stage cancer, vs. the standard of care alpha fetoprotein (AFP) test. The...
00:24 , Jun 6, 2018 |  BioCentury  |  Product Development

Second (Ex)act

Armed with Phase II data for its second DNA methylation test, Exact Sciences Corp. expects a repeat performance of the rapid launch trajectory its Cologuard colorectal cancer screening assay has enjoyed. Cologuard beat expectations for...
20:37 , Jun 5, 2018 |  BC Extra  |  Clinical News

Exact HCC assay significantly better than SOC

Exact Sciences Corp. (NASDAQ:EXAS) reported data showing that its hepatocellular carcinoma blood test had greater sensitivity and specificity in identifying HCC, especially early stage cancer, vs. the standard of care alpha fetoprotein (AFP) test. The...
05:50 , Jun 2, 2018 |  BioCentury  |  Product Development

Breaking from the herd

Behind the block of clinical studies on PD-1 and PD-L1 inhibitors, researchers are casting aside their herd mentality with a wide net of strategies to solve some of the most pressing problems in oncology, such...
14:45 , Apr 6, 2018 |  BC Week In Review  |  Clinical News

Lilly's Cyramza meets in biomarker-selected HCC population

Eli Lilly and Co. (NYSE:LLY) said second-line treatment with Cyramza ramucirumab (IMC-1121B, LY3009806) met the primary endpoint of improving overall survival (OS) compared with placebo in the Phase III REACH-2 trial to treat hepatocellular carcinoma...
19:33 , Apr 4, 2018 |  BC Extra  |  Clinical News

Lilly's Cyramza meets in biomarker-selected HCC population

Eli Lilly and Co. (NYSE:LLY) said second-line treatment with Cyramza ramucirumab met the primary endpoint of improving overall survival (OS) compared with placebo in the Phase III REACH-2 trial to treat hepatocellular carcinoma in patients...
23:17 , Sep 29, 2017 |  BioCentury  |  Strategy

Bridge to innovation

While Zai Lab Ltd. has joined the ranks of Chinese biotechs making a splash on NASDAQ, less noticed may be the first wave of China-based players moving into Boston to jump-start their push into novel...
19:25 , Sep 8, 2017 |  BC Week In Review  |  Company News

GSK exercises option for Adaptimmune’s NY-ESO SPEAR T cell therapy program

Adaptimmune Therapeutics plc (NASDAQ:ADAP) said GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) exercised a 2014 option for exclusive rights to Adaptimmune’s NY-ESO SPEAR T cell therapy program. The decision comes as Adaptimmune was preparing for a pivotal trial...
00:23 , Sep 8, 2017 |  BC Extra  |  Company News

GSK nabs Adaptimmune’s NY-ESO SPEAR T cell therapy program

Adaptimmune Therapeutics plc (NASDAQ:ADAP) gained $0.81 (12%) to $7.55 Thursday after GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) exercised a 2014 option for exclusive rights to Adaptimmune’s NY-ESO SPEAR T cell therapy program. The decision comes as Adaptimmune...